A new therapeutic target for proteasome inhibitor resistant multiple myeloma [ 2019 - ]

Also known as: 5011861

Research Grant

[Cite as]

Brief description Multiple myeloma (MM) is an incurable blood cancer for which novel therapeutic strategies are urgently required. Although MM patients have greatly benefited from the addition of the drug bortezomib to therapeutic regimens, resistance to bortezomib inevitably occurs. This proposal will examine ways to re-sensitise bortezomib-resistant MM by targeting lipid metabolism using new agents we have recently developed. By doing so, we hope to discover new therapies to extend the lives of MM patients.

Funding Amount $676,589.00

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]